Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway

A compound having formula (II):

• or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
• R1 is pyridyl substituted with one or more substituents independently selected from the group consisting of substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted heterocyclyl, halogen, aminocarbonyl, cyano, hydroxyalkyl, —OR, and —NR2, wherein each R is independently H, or a substituted or unsubstituted C1-4 alkyl;
• R2 is substituted or unsubstituted C1-8 alkyl;
• and
• R3 is H, or a substituted or unsubstituted C1-8 alkyl,
• wherein substituted means substituted with a substituent selected from the group consisting of halogen;
• alkyl;
• hydroxy;
• alkoxy;
• alkoxyalkyl;
• amino;
• alkylamino;
• carboxy;
• nitro;
• cyano;
• thiol;
• thioether;
• imine;
• imide;
• amidine;
• guanidine;
• enamine;
• aminocarbonyl;
• acylamino;
• phosphonato;
• phosphine;
• thiocarbonyl;
• alkylsulfonyl;
• sulfonamide;
• alkylsulfonylamino;
• acyl;
• ester;
• urea;
• urethane;
• oxime;
• hydroxylamine;
• alkoxyamine;
• aralkoxyamine;
• N-oxide;
• hydrazine;
• hydrazide;
• hydrazone;
• azide;
• isocyanate;
• isothiocyanate;
• cyanate;
• thiocyanate;
• oxo;
• B(OH)2;
• O(alkyl)aminocarbonyl;
• cycloalkyl, which may be monocyclic or fused or non-fused polycyclic, or a heterocyclyl, which may be monocyclic or fused or non-fused polycyclic;
• monocyclic or fused or non-fused polycyclic aryl or heteroaryl;
• aryloxy;
• hydroxyalkyl;
• aralkyl;
• aralkyloxy;
• heterocyclyloxy;
• heterocyclylalkyl;
• and heterocyclylalkoxy.